PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AbCellera Biologics Inc. (ABCL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCA00288U1066
CUSIP00288U106
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.38B
EPS-$0.51
Revenue (TTM)$38.03M
Gross Profit (TTM)$311.11M
EBITDA (TTM)-$212.81M
Year Range$3.87 - $8.05
Target Price$15.38
Short %10.80%
Short Ratio13.66

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABCL

AbCellera Biologics Inc.

Popular comparisons: ABCL vs. VOO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AbCellera Biologics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%OctoberNovemberDecember2024FebruaryMarch
-92.00%
39.68%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

AbCellera Biologics Inc. had a return of -17.51% year-to-date (YTD) and -36.27% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-17.51%7.28%
1 month-11.80%2.23%
6 months-11.80%14.98%
1 year-36.27%30.65%
5 years (annualized)N/A12.59%
10 years (annualized)N/A10.61%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-10.51%-1.17%
2023-29.50%-15.60%-10.65%14.60%21.23%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABCL
AbCellera Biologics Inc.
-0.66
^GSPC
S&P 500
2.64

Sharpe Ratio

The current AbCellera Biologics Inc. Sharpe ratio is -0.66. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.66
2.64
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AbCellera Biologics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-92.00%
-1.12%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AbCellera Biologics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AbCellera Biologics Inc. was 93.36%, occurring on Oct 27, 2023. The portfolio has not yet recovered.

The current AbCellera Biologics Inc. drawdown is 92.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.36%Dec 14, 2020723Oct 27, 2023

Volatility

Volatility Chart

The current AbCellera Biologics Inc. volatility is 13.58%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%OctoberNovemberDecember2024FebruaryMarch
13.58%
3.36%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Financials

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM2023202220212020
Revenue

Total Revenue

38.03M38.03M485.42M11.61M233.16M

Cost Of Revenue

76.42M30.89M66.44M45.52M27.14M

Gross Profit

-38.40M7.13M418.99M11.61M206.01M
Operating Expenses

Selling, General & Admin Expenses

61.00M61.00M55.49M2.75M11.91M

R&D Expenses

175.66M175.66M107.88M62.06M29.39M

Total Operating Expenses

261.08M261.08M191.92M13.95M41.66M
Income

Income Before Tax

-174.03M-174.03M239.10M-2.21M157.83M

Operating Income

-233.83M-237.21M216.51M-4.12M156.03M

EBIT

-223.05M-223.05M216.51M-2.00M156.03M

Earnings From Continuing Operations

-146.40M-146.40M158.52M153.46M118.92M

Net Income

-146.40M-146.40M158.52M-2.21M118.92M

Income Tax Expense

-27.63M-27.63M80.58M65.69M38.92M

Interest Expense

16.73M0.004.05M209.20K6.51M

Other Non-Operating Income (Expenses)

16.53M6.78M22.59M1.91M1.80M

Extraordinary Items

0.000.000.000.000.00

Discontinued Operations

0.000.000.000.000.00

Effect Of Accounting Charges

0.000.000.000.000.00

Non Recurring

0.000.0066.44M45.52M0.00

Minority Interest

0.000.000.000.000.00

Other Items

0.000.000.000.000.00
Values in USD except per share items